Infliximab and adalimumab in TNF-αnaïve Crohn's disease patients: Austrian multicentre cohort study

Background/Aim: Tumor necrosis factor-α inhibitors (TNFi), infliximab (IFX) & adalimumab (ADA) revolutionized the treatment of Crohn's disease (CD). However, despite their broad clinical use, studies comparing their efficacy in TNF-α naïve CD patients are missing. Patients/Methods: Consecutive TNF-α naïve patients with luminal CD from four tertiary centers were retrospectively analyzed for short- and long-term efficacy of IFX and ADA. Stepwise logistic regression was performed to identify predictors of remission at week 12 and month 12. Cox-regression analysis was performed to evaluate time to loss of remission.…